News Headlines Article

The Drug Price Reform Debate
HealthLeaders Media

The marketing of an ever-growing number of new drugs that come with eye-popping price tags is spurring a drive to develop value-based pricing models.

“Pricing is the issue,” says Samuel Nussbaum, MD, executive VP for clinical health policy and chief medical officer for Indianapolis-based WellPoint, Inc. He says the healthcare industry faces an unsustainable cost trend for so-called specialty drugs such as medications that are targeted at specific forms of cancer capable of treating relatively small pools of patients annually.